This study looks at the long-term safety of a medicine called astegolimab for people with Chronic Obstructive Pulmonary Disease (COPD). COPD is a lung disease that makes it hard to breathe. Astegolimab is being tested to see how safe it is and if it helps people with COPD. This study is for people who have already participated in one of two previous studies and completed 52 weeks of treatment.

Astegolimab is being compared to a placebo, which is a treatment with no active medicine, to see if it works better. To be part of this new study, you need to have completed the full treatment in the earlier study without any major issues. You cannot join if you stopped the earlier study early or have any new serious health problems since joining the earlier study.

• The study checks how safe astegolimab is over a long time.
• You must have completed 52 weeks in the earlier study to join.
• The study is only for those without new major health issues.